Rituximab biosimilar - TOT Biopharm

Drug Profile

Rituximab biosimilar - TOT Biopharm

Alternative Names: RTIA 07; TOT 101

Latest Information Update: 29 May 2015

Price : $50

At a glance

  • Originator TOT Biopharm
  • Class Antineoplastics; Antirheumatics; Follicle stimulating hormones; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Non-Hodgkin's lymphoma

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top